PPI inhibitor and stabilizer development in human diseases.
1Pediatric Pulmonology Division, Department of Pediatrics, Case Western Reserve University School of Medicine, 2109 Adelbert Rd, Biomedical Research Building Room 835, Cleveland, OH, USA; InterRayBio, LLC, Baltimore, MD, USA.
Drug Discovery Today. Technologies
|December 14, 2017
Summary
Protein-protein interactions (PPIs) are crucial in biology and medicine. This review covers methods for studying PPIs and highlights successful drug development targeting these interactions.
Area of Science:
- Biochemistry and Molecular Biology
- Pharmacology and Drug Discovery
Background:
- Protein-protein interactions (PPIs) are fundamental to biological processes and cellular signaling.
- Membrane proteins are key mediators of intercellular communication and sensing, influencing downstream signaling events.
- Modulators of PPIs are of significant interest for developing therapeutics for various diseases.
Purpose of the Study:
- To provide an overview of techniques for protein-protein interaction (PPI) elucidation.
- To present case studies of PPI exploitation in drug discovery and development.
Main Methods:
- Review of current methodologies for identifying and characterizing PPIs.
- Analysis of case studies involving PPI modulators from early discovery to approved drugs.
Main Results:
- Recent advancements have made PPI exploitation more accessible for therapeutic development.
- Several successful drug development programs targeting PPIs have reached the market.
Conclusions:
- Understanding and targeting PPIs, particularly those involving membrane proteins, offers significant therapeutic potential.
- Continued innovation in PPI elucidation techniques will drive the development of novel drugs for unmet medical needs.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
527
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
527
01:23Dipeptidyl Peptidase 4 Inhibitors
729
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
729
01:42Phosphoinositides and PIPs
10.3K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
10.3K
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
227
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
227
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
17
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
17
01:29Pharmacogenomics: Identification of New Drug Targets
9
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
9